InspireMD Inc. (NSPR)
| Market Cap | 30.66M |
| Revenue (ttm) | 2.46M |
| Net Income (ttm) | -11.81M |
| Shares Out | 7.91M |
| EPS (ttm) | -3.98 |
| PE Ratio | n/a |
| Forward PE | 11.70 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 29 |
| Last Price | $3.93 |
| Previous Close | $3.82 |
| Change ($) | 0.11 |
| Change (%) | 2.88% |
| Day's Open | 3.84 |
| Day's Range | 3.76 - 3.95 |
| Day's Volume | 69,805 |
| 52-Week Range | 3.60 - 22.20 |
TEL AVIV, Israel, July 23, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD...
TEL AVIV, Israel, June 02, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq-CM: NSPR) developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by Carotid Artery Disea...
Ticker to remain NSPR Ticker to remain NSPR
TEL AVIV, Israel, May 14, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of ...
TEL AVIV, Israel, May 12, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of...
Company Completes Up-List to Nasdaq Capital Market, with Trading Becoming Effective May 21, 2021
Ticker to remain NSPR Ticker to remain NSPR
TEL AVIV, Israel, April 29, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid ar...
Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts behind those...
InspireMD has vastly reduced the number of its shares trading ahead of a likely move to a Nasdaq listed. Conversion of NSPR stock warrants and preferred shares will be more difficult now.
TEL AVIV, Israel, April 19, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke cause...
Penny Stocks Continue to Make Big Headway in April 2021 The post Best Penny Stocks To Buy Today? 3 Stocks To Watch In April 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | Penn...
TEL AVIV, Israel, April 14, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke cause...
TEL AVIV, Israel, March 22, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid ar...
Management to host investor conference call today, March 9, at 8:30am ET Management to host investor conference call today, March 9, at 8:30am ET
Earnings conference call to be held Tuesday, March 9, 2021 at 8:30 a.m. ET Earnings conference call to be held Tuesday, March 9, 2021 at 8:30 a.m. ET
TEL AVIV, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery ...
TEL AVIV, Israel, Feb. 09, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery ...
TEL AVIV, Israel, Feb. 08, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. ("InspireMD") (NYSE:NSPR), a medical device company focused on the development and commercialization of proprietary MicroNet stent pla...
TEL AVIV, Israel, Feb. 04, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. ("InspireMD") (NYSE:NSPR), a medical device company focused on the development and commercialization of proprietary MicroNet stent pla...
InspireMD Secures Partner for Intended Registration and Distribution of CGuard EPS in Mainland China
New Chinese Distributor Will Also Invest in At-The-Market Private Placement New Chinese Distributor Will Also Invest in At-The-Market Private Placement
TEL AVIV, Israel, Jan. 26, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid art...
InspireMD, Inc. (NSPR) CEO Marvin Slosman on Q3 2020 Results - Earnings Call Transcript
TEL AVIV, Israel, Nov. 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by...
TEL AVIV, Israel, Nov. 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by...
Earnings conference call to be held Monday, November 9, 2020 at 8:30 a.m. ET Earnings conference call to be held Monday, November 9, 2020 at 8:30 a.m. ET
TEL AVIV, Israel, Oct. 13, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid art...
TEL AVIV, Israel, Oct. 06, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by...
Advancing the CARENET-III study of CGuard System for Stroke Prevention in the United States Advancing the CARENET-III study of CGuard System for Stroke Prevention in the United States
IDE Approval to Pave the Way for Pivotal Study of CGuard System for Carotid Artery Disease and Stroke Prevention in the United States IDE Approval to Pave the Way for Pivotal Study of CGuard System for ...
TEL AVIV, Israel, Sept. 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid ...
TEL AVIV, Israel, Aug. 25, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment...
TEL AVIV, Israel, Aug. 10, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment...
InspireMD's (NSPR) CEO Marvin Slosman on Q2 2020 Results - Earnings Call Transcript
In the second quarter the Company was granted approval to market its CGuard™ MicroNet stent in Brazil and completed an $11.5 million capital raise; reported outstanding results in studies treating pa...
Conference Call to be held Wednesday, August 5, 2020 at 8:30am ET Conference Call to be held Wednesday, August 5, 2020 at 8:30am ET
Conference Call to be held Thursday, August 5, 2020 at 8:30am ET Conference Call to be held Thursday, August 5, 2020 at 8:30am ET
In a head-to-head evaluation, significantly fewer silent brain infarcts were associated with CGuard™ EPS versus Acculink™ at 30 days post-procedure In a head-to-head evaluation, significantly fewer sile...
Results indicate that 12 months after carotid intervention the CGuard EPS MicroNET-covered stent delivers sustained protection against postprocedural neurologic events
TEL AVIV, Israel, June 08, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid a...
TEL AVIV, Israel, June 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid a...
InspireMD, Inc. (NSPR) CEO Marvin Slosman on Q1 2020 Results - Earnings Call Transcript
First quarter revenue growth driven by continued strong uptake of the CGuard™ Embolic Prevention System (EPS) in the company’s major markets
InspireMD's (NSPR) CEO Marvin Slosman on Q4 2019 Results - Earnings Call Transcript
Case demonstrates ease-of-use and exceptional patient safety features of CGuard™ EPS Case demonstrates ease-of-use and exceptional patient safety features of CGuard™ EPS
Bet on these top-ranked stocks with rising P/E to realize outsized gains.
InspireMD, Inc. (NSPR) CEO Jim Barry on Q3 2019 Results - Earnings Call Transcript
TEL AVIV, Israel, Sept. 19, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid ...
TEL AVIV, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid ...
TEL AVIV, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid arte...
About NSPR
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing ... [Read more...]
| Industry Medical Devices | |
| CEO Alan Milinazzo | Employees 45 |
| Stock Exchange NASDAQ | Ticker Symbol NSPR |
Financial Performance
In 2020, InspireMD's revenue was $2.49 million, a decrease of -33.22% compared to the previous year's $3.72 million. Losses were -$10.54 million, 5.02% more than in 2019.
Analyst Forecasts
According to 2 analysts, the average rating for InspireMD stock is "Buy." The 12-month stock price forecast is 16.50, which is an increase of 319.85% from the latest price.